These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Nephrogenic systemic fibrosis and class labeling of gadolinium-based contrast agents by the Food and Drug Administration. Yang L; Krefting I; Gorovets A; Marzella L; Kaiser J; Boucher R; Rieves D Radiology; 2012 Oct; 265(1):248-53. PubMed ID: 22923714 [TBL] [Abstract][Full Text] [Related]
5. [Betamethasone in the prevention of allergic complications caused by intravenous iodine contrast media]. Chevrot A; Chevrot L; Sarrat P; Wallays C Ann Radiol (Paris); 1988; 31(3):193-6. PubMed ID: 3218843 [No Abstract] [Full Text] [Related]
6. [Experiences with the new water-soluble contrast medium Dimer X for lumbal myelography]. Rey G Radiologe; 1973 Dec; 13(12):547-50. PubMed ID: 4784835 [No Abstract] [Full Text] [Related]
7. [Problems and risks in the intravenous administration of iodinated contrast media]. Sehr A; Strejcek J Cesk Radiol; 1987 Dec; 41(6):354-61. PubMed ID: 3442865 [No Abstract] [Full Text] [Related]
8. Inadvertent intrathecal use of ionic contrast media. Chaloupka JC AJNR Am J Neuroradiol; 1993; 14(3):784. PubMed ID: 8517375 [No Abstract] [Full Text] [Related]
9. Immediate reactions following iodinated contrast media injection: a study of 38 cases. Dewachter P; Laroche D; Mouton-Faivre C; Bloch-Morot E; Cercueil JP; Metge L; Carette MF; Vergnaud MC; Clément O Eur J Radiol; 2011 Mar; 77(3):495-501. PubMed ID: 19833466 [TBL] [Abstract][Full Text] [Related]
10. Deaths related to iodinated contrast media reported spontaneously to the U.S. Food and Drug Administration, 1978-1994: effect of the availability of low-osmolality contrast media. Spring DB; Bettmann MA; Barkan HE Radiology; 1997 Aug; 204(2):333-7. PubMed ID: 9240516 [TBL] [Abstract][Full Text] [Related]
11. [Experimental studies on the elimination and neurotoxicity of a new water soluble contrast medium for lumbosacral myelography]. Braband H; Lessmann HD; Wenker H Radiologe; 1972 Feb; 12(2):66-8. PubMed ID: 5027901 [No Abstract] [Full Text] [Related]
12. Contrast agent approved for liver imaging. Thompson CA Am J Health Syst Pharm; 2008 Aug; 65(16):1490. PubMed ID: 18693195 [No Abstract] [Full Text] [Related]
13. Nonfatal adverse reactions to iodinated contrast media: spontaneous reporting to the U.S. Food and Drug Administration, 1978-1994. Spring DB; Bettmann MA; Barkan HE Radiology; 1997 Aug; 204(2):325-32. PubMed ID: 9240515 [TBL] [Abstract][Full Text] [Related]
14. [Side effects of 2 water-soluble contrast media used in myelography]. Caillé JM Ann Radiol (Paris); 1983 Dec; 26(8 Pt 2):779-82. PubMed ID: 6689467 [No Abstract] [Full Text] [Related]
15. [Contrast media in use in myelography and ventriculography: current status and future prospects]. Gonsette RE Radiol Med; 1980 Apr; 66(4):195-202. PubMed ID: 6256823 [No Abstract] [Full Text] [Related]
17. Nephrogenic systemic fibrosis and gadolinium-enhanced magnetic resonance imaging: does a US Food and Drug Administration alert influence practice patterns in CKD? Martin DR Am J Kidney Dis; 2010 Sep; 56(3):427-30. PubMed ID: 20728788 [No Abstract] [Full Text] [Related]